DoW Pancreatic Cancer Research Program, Translational Research Partnership Award
About
Summary: The fiscal year 2026 (FY26) Pancreatic Cancer Research Program (PCARP) Translational Research Partnership Award supports partnerships between clinicians, population scientists, applied scientists and/or basic scientists that will accelerate the movement of promising ideas in pancreatic cancer toward clinical applications. The partnership must include at least one member with expertise in pancreatic cancer research or pancreatic cancer patient care. All applications must address at least one of the FY26 PCARP Focus Areas. · This award mechanism requires preliminary data to support feasibility of the research hypothesis(es) and research approaches. However, these data do not necessarily need to originate from studies of pancreatic cancer. Applications can support retrospective tissue analysis, correlative studies and pilot clinical trials; however, this mechanism does not allow large-scale clinical trials. · The Translational Research Partnership Award requires two Principal Investigators (PIs) referred to as the Initiating PI and the Partnering PI. Only the Initiating PI will submit a pre-application, but both PIs will need to submit at the full application stage. The partnering PI’s application is an abbreviated package specific to their distinct portion of the research project. Be advised, all associated applications for a research project may be withdrawn if the initiating or partnering application is rejected or administratively withdrawn.
The DoW Pancreatic Cancer Research Program (PCARP) Translational Research Partnership Award supports collaborative research teams working to advance pancreatic cancer discoveries from the laboratory to clinical practice. This grant is designed for partnerships between clinicians, population scientists, applied scientists, and basic scientists who are committed to accelerating promising pancreatic cancer research ideas toward real-world clinical applications. At least one team member must have expertise in pancreatic cancer research or patient care. This award mechanism is ideal for research teams with preliminary data demonstrating feasibility of their research hypotheses and approaches. Fundable projects include retrospective tissue analyses, correlative studies, and pilot clinical trials—though large-scale clinical trials are not supported under this mechanism. The program requires two Principal Investigators: an Initiating PI who submits the pre-application and a Partnering PI who submits an abbreviated application focusing on their distinct research contribution. Researchers should note that rejection or administrative withdrawal of either the initiating or partnering application may result in withdrawal of all associated applications. All proposals must address at least one of the FY26 PCARP Focus Areas to be considered competitive for funding.
Funding Facts
● Applications openDeadline
October 7, 2026
Who can apply
Last verified July 5, 2026 · Source: Grants.gov
Grant Details
Funding Range
Varies by cycle
Deadline
2026-10-07
Grant Type
federal
Application Cycle
Annual
Best For
Research partnerships advancing pancreatic cancer discoveries toward clinical applications
Frequently Asked Questions
Who is eligible for DoW Pancreatic Cancer Research Program, Translational Research Partnership Award?
This award supports collaborative research partnerships between clinicians, population scientists, applied scientists, and/or basic scientists. At least one team member must have expertise in pancreatic cancer research or pancreatic cancer patient care. The partnership requires two Principal Investigators: an Initiating PI and a Partnering PI. For complete eligibility requirements and institutional qualifications, please consult the official Department of War (DoW) funding announcement or visit the program's official website.
How much funding does DoW Pancreatic Cancer Research Program, Translational Research Partnership Award provide?
Specific funding amounts are not listed in the current program information. Award amounts may vary by funding cycle. Contact the program directly or visit the official DoW PCARP website for detailed information about FY26 funding levels and budget parameters.
How do I apply for DoW Pancreatic Cancer Research Program, Translational Research Partnership Award?
The application process requires submission of a pre-application from the Initiating PI, followed by full applications from both the Initiating PI and the Partnering PI at the next stage. The Partnering PI submits an abbreviated application specific to their research contribution. The deadline for FY26 applications is October 7, 2026. For detailed submission instructions, required documentation, and the full application process, visit the official DoW Pancreatic Cancer Research Program website.
What can DoW Pancreatic Cancer Research Program, Translational Research Partnership Award funding be used for?
Funding supports translational research projects designed to move pancreatic cancer research discoveries toward clinical applications. Fundable activities include retrospective tissue analysis, correlative studies, and pilot clinical trials. Applications must include preliminary data supporting the feasibility of research hypotheses and approaches, though this preliminary data does not need to originate from pancreatic cancer studies. Large-scale clinical trials are not eligible under this mechanism. All proposals must address at least one FY26 PCARP Focus Area.
Last updated: July 5, 2026